A PHASE 2A, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-06651600 AND PF 06700841 AS INDUCTION AND OPEN LABEL EXTENSION TREATMENT IN SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE

drug protocol number
B7981007
drug sponsor
Pfizer
drug study
PF-06651600
drug trial site
NGHA-R,KKUH, King Abdulaziz Medical City NG (Jeddah)
drug status
Completed
drug phase